 |
|
Pharmaceutical Manufacturer Sponsorship and Drug Information
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The recent article "Dose Discrepancies Between the Physicians' Desk Reference and the Medical Literature, and Their Possible
Role in the High Incidence of Dose-Related Adverse Drug Events"1
is timely and provocative. As clinicians involved with the education of medical
practitioners, we frequently discuss the limitations of the Physicians' Desk Reference (PDR). Inaccuracies
in PDR overdose management guidelines have been described
elsewhere.2 Although some practitioners
are aware of the PDR's limitations, we believe that
most clinicians have difficulty appreciating the consequences of these information
discrepancies. This is exemplified by the persistent high utilization of the PDR despite the availability of alternative references,
as pointed out by the authors.
The PDR dosing information is limited to Food
and Drug Administration–approved product labeling. This creates a number
of potential limitations. In the absence of periodic literature reviews and
dosing reevaluation, discrepancies between PDR recommendations
and the best available evidence are . . . [Full Text of this Article]
RELATED ARTICLE
Dose Discrepancies Between the Physicians' Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events
Jay S. Cohen
Arch Intern Med. 2001;161(7):957-964.
ABSTRACT
| FULL TEXT
|
